Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)

American Journal of Cardiology

Volumn 113, Issue 2, 2014, Pages 321-327

  Van Tassell, Benjamin Wallace ^a   Arena, Ross ^b   Biondi Zoccai, Giuseppe ^c   McNair Canada, Justin ^a   Oddi, Claudia ^a   Abouzaki, Nayef Antar ^a   Jahangiri, Arehzo ^a   Falcao, Raquel Appa ^a   Kontos, Michael Christopher ^a   Shah, Keyur Bharat ^a   Voelkel, Norbert Felix ^a   Dinarello, Charles Anthony ^d   Abbate, Antonio ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CARBON DIOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; OXYGEN; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SPIRONOLACTONE;

ADULT; AEROBIC CAPACITY; AEROBIC EXERCISE; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; INJECTION SITE REACTION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84891633095     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.08.047     Document Type: Article

References (29)

1. J.E. Udelson Heart failure with preserved ejection fraction Circulation 124 2011 e540 e543
2. B.A. Borlaug, and W.J. Paulus Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment Eur Heart J 32 2011 670 679
3. W.J. Paulus, C. Tschope, J.E. Sanderson, C. Rusconi, F.A. Flachskampf, F.E. Rademakers, P. Marino, O.A. Smiseth, G. De Keulenaer, A.F. Leite-Moreira, A. Borbely, I. Edes, M.L. Handoko, S. Heymans, N. Pezzali, B. Pieske, K. Dickstein, A.G. Fraser, and D.L. Brutsaert How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur Heart J 28 2007 2539 2550
4. Y. Michowitz, Y. Arbel, D. Wexler, D. Sheps, O. Rogowski, I. Shapira, S. Berliner, G. Keren, J. George, and A. Roth Predictive value of high sensitivity CRP in patients with diastolic heart failure Int J Cardiol 125 2008 347 351
5. S.J. Shah, G.M. Marcus, I.L. Gerber, B.H. McKeown, J.C. Vessey, M.V. Jordan, M. Huddleston, E. Foster, K. Chatterjee, and A.D. Michaels High-sensitivity C-reactive protein and parameters of left ventricular dysfunction J Card Fail 12 2006 61 65
6. K.P. Liang, E. Myasoedova, C.S. Crowson, J.M. Davis, V.L. Roger, B.L. Karon, D.D. Borgeson, T.M. Therneau, R.J. Rodeheffer, and S.E. Gabriel Increased prevalence of diastolic dysfunction in rheumatoid arthritis Ann Rheum Dis 69 2010 1665 1670
7. I. Ikonomidis, J.P. Lekakis, M. Nikolaou, I. Paraskevaidis, I. Andreadou, T. Kaplanoglou, P. Katsimbri, G. Skarantavos, P.N. Soucacos, and D.T. Kremastinos Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis Circulation 117 2008 2662 2669
8. I. Ikonomidis, S. Txortzis, I. Andreadou, P. Dasou, C. Katseli, P. Kastimbru, I. Paraskevaidis, J. Parissis, J. Lekakis, and M. Anastasious-Nana Inhibition of interleukin-1 activity by anakinra improves left ventricular myocardial deformation and torsion in patients with CAD and coexistent rheumatoid arthritis: a randomized trial Eur Heart J 33 Suppl 1 2012 720 721
9. C.A. Dinarello Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Blood 117 2011 3720 3732
10. B.W. Van Tassell, S. Toldo, E. Mezzaroma, and A. Abbate Targeting Interleukin-1 in heart disease Circulation 128 2013 1910 1923
11. A. Abbate, B.W. Van Tassell, G. Biondi-Zoccai, M.C. Kontos, J.D. Grizzard, D.W. Spillman, C. Oddi, C.S. Roberts, R.D. Melchior, G.H. Mueller, N.A. Abouzaki, L.R. Rengel, A. Varma, M.L. Gambill, R.A. Falcao, N.F. Voelkel, C.A. Dinarello, and G.W. Vetrovec Effects of Interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-anakinra remodeling trial (2) (VCU-ART2) pilot study] Am J Cardiol 111 2013 1394 1400
12. B.W. Van Tassell, R.A. Arena, S. Toldo, E. Mezzaroma, T. Azam, I.M. Seropian, K. Shah, J. Canada, N.F. Voelkel, C.A. Dinarello, and A. Abbate Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure PLoS One 7 2012 e33438
13. N. Rifai, R.P. Tracy, and P.M. Ridker Clinical efficacy of an automated high-sensitivity C-reactive protein assay Clin Chem 45 1999 2136 2141
14. R. Arena, J. Myers, and M. Guazzi The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review Heart Fail Rev 13 2008 245 269
15. M.G. Kenward, and B. Jones The analysis of data 2×2 cross-over trials with baseline measurements Stat Med 6 1987 911 926
16. B.W. Van Tassell, I.M. Seropian, S. Toldo, E. Mezzaroma, and A. Abbate Interleukin-1β induces a reversible cardiomyopathy in the mouse Inflamm Res 62 2013 637 640
17. L.P. Cahalin, P. Chase, R. Arena, J. Myers, D. Bensimhon, M.A. Peberdy, E. Ashley, E. West, D.E. Forman, S. Pinkstaff, C.J. Lavie, and M. Guazzi A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure Heart Fail Rev 18 2013 79 94
18. R. Arena, J. Myers, M.A. Williams, M. Gulati, P. Kligfield, G.J. Balady, E. Collins, G. Fletcher, American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology, and American Heart Association Council on Cardiovascular Nursing Assessment of functional capacity in clinical and research settings: a scientific statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing Circulation 116 2007 329 343
19. 2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training Circ Heart Fail 5 2012 579 585
20. M.M. Redfield, B.A. Borlaug, G.D. Lewis, S.F. Mohammed, M.J. Semigran, M.M. Lewinter, A. Deswal, A.F. Hernandez, K.L. Lee, E. Braunwald Heart Failure Clinical Research Network PhosphdiesteRasE-5 inhibition to improve CLinical Status and EXercise capacity in diastolic heart failure (RELAX) trial: rationale and design Circ Heart Fail 5 2012 653 659
21. R. Arena, R. Humphrey, and M.A. Peberdy Relationship between the Minnesota Living with Heart Failure Questionnaire and key ventilatory expired gas measures during exercise testing in patients with heart failure J Cardiopulm Rehabil 22 2002 273 277
22. L.C. Davies, R. Wensel, P. Georgiadou, M. Cicoira, A.J. Coats, M.F. Piepoli, and D.P. Francis Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope Eur Heart J 27 2006 684 690
23. A. Abbate, M.C. Kontos, J.D. Grizzard, G.G. Biondi-Zoccai, B.W. Van Tassell, R. Robati, L.M. Roach, R.A. Arena, C.S. Roberts, A. Varma, C.C. Gelwix, F.N. Salloum, A. Hastillo, C.A. Dinarello, G.W. Vetrovec VCU-ART Investigators Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] pilot study) Am J Cardiol 105 2010 1371 1377
24. D.C. Poole, D.M. Hirai, S.W. Copp, and T.I. Musch Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance Am J Physiol Heart Circ Physiol 302 2012 H1050 H1063
25. V.Y. Anjan, T.M. Loftus, M.A. Burke, N. Akhter, G.C. Fonarow, M. Gheorghiade, and S.J. Shah Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction Am J Cardiol 110 2012 870 876
26. M.R. Mehra, P.A. Uber, M.H. Park, R.L. Scott, H.O. Ventura, B.C. Harris, and E.D. Frohlich Obesity and suppressed B-type natriuretic peptide levels in heart failure J Am Coll Cardiol 43 2004 1590 1595
27. M.T. Maeder, P. Rickenbacher, H. Rickli, H. Abbühl, M. Gutmann, P. Erne, A. Vuilliomenet, M. Peter, M. Pfisterer, H.P. Brunner-La Rocca TIME-CHF Investigators N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF) Eur J Heart Fail 15 2013 1148 1156
28. J.J. McMurray, J. Kjekshus, L. Gullestad, P. Dunselman, A. Hjalmarson, H. Wedel, M. Lindberg, F. Waagstein, P. Grande, J. Hradec, G. Kamenský, J. Korewicki, T. Kuusi, F. Mach, N. Ranjith, J. Wikstrand CORONA Study Group Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis Circulation 120 2009 2188 2196
29. P.M. Ridker, T. Thuren, A. Zalewski, and P. Libby Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J 162 2011 597 605